Evolus Reports Second Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire • 08/05/25
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading NeurotoxinsBusiness Wire • 07/31/25
Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to DeclineZacks Investment Research • 07/29/25
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in FranceBusiness Wire • 07/09/25
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid GelsBusiness Wire • 05/22/25
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial FlexibilityBusiness Wire • 05/05/25
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid GelsBusiness Wire • 04/15/25
Evolus to Participate in The Needham 24th Annual Virtual Healthcare ConferenceBusiness Wire • 03/25/25
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 GuidanceBusiness Wire • 03/04/25
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor ConferencesBusiness Wire • 02/27/25
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness SummitBusiness Wire • 02/20/25